CEO GREETING
Over the past 20 years, our group has been conducting foundational research on placenta-based therapies.
Our commitment to the subject has resulted in the discovery of the biological value of the placenta, which was usually discarded after childbirth. Additionally, our studies have published a significant number of noteworthy articles in journals on a national and worldwide level, as well as patents and clinical trials. We are developing placenta-based therapeutics in the fields of infertility, liver and ophthalmology. Based on our cutting-edge technology and professionalism, PLABiologics aims to deliver the most natural type of medicine as an alternative to chemical therapy. More and more unsolved biological questions are rising due to the rapid progression of pollution and an aging population. We PLABiologics can contribute to a healthier and more promising future for humanity.
PLABiologics CEO Gi Jin Kim